New safety information

Posted 2 years ago

There is a risk of necrotising fasciitis of the perineum (Fournier’s gangrene) with the SGLT2 inhibitor class issued by AstraZeneca, Boehringer Ingelheim and Merck Sharp & Dohme.

Click here to read the joint safety commuincation for more details.

Any questions regarding this communication, should be kindly directed to the relevant company contact points.